RxDoctor Payments Data

Brenda Loubriel Rivera, MD

Pulmonary Disease · Manati, PRNPI 1528086998

Payments from drug & device makers

$1,839in general payments, 2019–2025

Across 82 payments — averaging $22.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$333
  • Boehringer Ingelheim$322
  • Chiesi USA, Inc.$46
  • Edwards Lifesciences$45
  • E.r. Squibb & Sons, L.L.C.$25
  • plus $41 from 2 others

What the payments were for

  • Food & beverage$1,839100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK50$1,027
AstraZeneca12$333
Boehringer Ingelheim13$322
Chiesi USA, Inc.3$46
Edwards Lifesciences1$45
E.r. Squibb & Sons, L.L.C.1$25
PBG Puerto Rico LLC1$25
Mylan LLC1$16

How this compares

$1,839 in reported general payments places this provider in the 35th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$14,134
Medicare patients
42
Services billed
149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter638$425,215
Breo ElliptaFluticasone/Vilanterol645$267,135
Spiriva RespimatTiotropium Bromide389$210,757
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate336$93,631
Stiolto RespimatTiotropium Br/Olodaterol Hcl132$64,692
Breztri AerosphereBudesonide/Glycopyr/Formoterol99$64,583
Arnuity ElliptaFluticasone Furoate194$41,731
SymbicortBudesonide/Formoterol Fumarate118$28,854
Atrovent HfaIpratropium Bromide55$26,268
Albuterol Sulfate HfaAlbuterol Sulfate615$24,693
Advair HfaFluticasone Propion/Salmeterol61$22,359
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr36$17,197
Fluticasone Propionate HfaFluticasone Propionate56$17,157
Fluticasone Propionate989$15,874
Montelukast Sodium1,754$14,833

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta$1,027$751,2781,513 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$322$275,449521 claims
AstraZenecaBreztri Aerosphere, Symbicort$333$93,438217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in Manati

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →